Daré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study
Daré Bioscience (DARE) said clinical data from a Phase 1 study of its investigational Sildenafil Cream, 3.6%, will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) in Orlando, Florida. The presentation will compare…